Amol Akhade/hiranandanihospital.org
May 15, 2025, 09:53
Amol Akhade: B7-H4 ADCs Emerge as New Hope in Breast Cancer
Amol Akhade, Consultant Medical Oncologist at Suyog Cancer Clinics, shared a post on X:
“New data from ESMO Breast 25
B7-H4 ADCs emerge as new hope in breast cancer!
Puxitatug Samrotecan in HR+/HER2– mBC (Topo1i-naïve)
B7-H4+ in 45%
ORR: 40% (1.6 mg/kg)
Low ILD and discontinuation
HER2-low? Biomarker timing?
Emiltatug Ledadotin in B7-H4 high TNBC (Topo1i-pretreated)
ORR: 23% overall | 29% in ≤4 prior lines
0% response in B7-H4 low
PFS: 16 wks (B7-H4 high) vs 6.4 wks (low)
Manageable toxicity
Takeaway
B7-H4 expression matters.
Next-gen ADCs may still shine post-TROP2/HER2 failures!
More posts featuring Amol Akhade.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 15, 2025, 18:17
May 15, 2025, 17:41
May 15, 2025, 17:00
May 15, 2025, 16:42